Anavex Life Sciences (AVXL) announced a presentation of phase 2B/3 Anavex 2-73-AD-004 at clinical trials on Alzheimer's Disease Congress 2022 and findings will be published in a peer reviewed journal. Anavex Life Sciences (AVXL) is a clinical-stage biopharmaceutical company that develops therapeutics for neurodegenerative and neurodevelopmental disorders. Their lead compound Anavex2-73 is being developed to treat Alzheimer's, Parkinson's, and other central nervous system diseases. George Tsilis weighs in on how AVXL compares to BIIB, ESALY, and LLY.
17 Oct 2022